MaxCyte Reports Second Quarter 2026 Financial Results
MaxCyte reported Q2 2026 total revenue of $7.3 million, down 15% year-over-year, but significantly narrowed its net loss to $8.9 million from $12.4 million in the prior year, driven by lower operating expenses. Following the quarter end, the company announced a strategic multi-platform technology license partnership with Genentech and has repurchased approximately $5.5 million of its common stock under a $10 million authorization.
Key figures
- Revenue
- $7.3 million
- Guidance
- FY26 revenue $30 million - $32 million; year-end cash > $130.5 million
- Revenue Yoy
- -15%
- Net loss
- $8.9 million
- Spl revenue
- $0.8 million
- Cash balance
- $141.9 million
- Core revenue
- $6.5 million
- Gross margin
- 77%
- Buyback repurchased
- $5.5 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.